Skip to main content
Fig. 4 | Molecular Neurodegeneration

Fig. 4

From: Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

Fig. 4

A scatter plot of the levels of plasma p-tau181 versus those of CSF p-tau181 in the patients of Cohort 3 (n = 11) and a linear regression line for the correlation of those two parameters. There is a significant correlation between the levels of plasma and CSF p-tau181 in this small cohort (R2 = 0.4525, p = 0.023, n = 11, Pearson correlation)

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326